Will Hospira’s Epogen Biosimilar Follow Sandoz’s Filgrastim Playbook?
This article was originally published in The Pink Sheet Daily
Hospira’s 351(k) application includes two comparative safety and efficacy studies and two open-label long-term safety studies for epoetin biosimilar.
You may also be interested in...
Physicians appear more willing to prescribe Hospira’s Inflectra, a biosimilar version of J&J’s Remicade, to new patients in countries in Europe where it is available, but less inclined to switch patients already taking the brand. The company’s experience in Europe could offer lessons for manufacturers looking to bring biosimilars to market in the US.
Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.